Posted Mon, 04/01/2013 - 06:00
ImaginAb is featured in the April 2013 issue of Nature Reviews - Drug Discovery.
The article, focused on emergent technology in Molecular Imaging, features an interview with ImaginAb's CEO Dr. Christian Behrenbruch. It includes an analysis of molecular imaging, including immuno-PET, as an indispensible tool for therapeutic development.
Read the article here: April 2013 Nature Reviews.
Posted Mon, 04/01/2013 - 02:00
LOS ANGELES, April 1, 2013 -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has changed its name to AmaginAb.
Posted Fri, 03/22/2013 - 12:39
ImaginAb’s Series A Financing Round is mentioned in the current issue of Nature Biotechnology. Read the article here.
Posted Fri, 03/22/2013 - 12:37
ImaginAb is pleased to announce its sponsorship of the Singapore Radiological Society & College of Radiologists, Singapore 22nd Annual Scientific Meeting (SRS & CRS 22nd ASM). The focus of this year’s conference is “Advances in Oncologic Imaging and Therapy.”
Posted Thu, 01/03/2013 - 13:42
ImaginAb's CEO, Christian Behrenbruch, will speak at the EMIT : Targeted Radiotherapy Summit in Washington DC on the 31st of January.
Chris was recently interviewed by the conference organizers and offers some thoughts on the future of integrated radioimmunotherapy and imaging - read the interview here.